Barrow Neurological Institute has embarked on a groundbreaking clinical study, securing a $5 million grant from the Arizona Department of Health Services. This ambitious project aims to investigate ibogaine as a potential treatment for neurological disorders, particularly traumatic brain injury (TBI). Led by a multidisciplinary team, the study will explore ibogaine's impact on brain chemistry and its potential to improve post-traumatic stress disorder (PTSD) symptoms, cognitive function, and overall quality of life.
The study's significance lies in addressing a critical gap in TBI treatment. Approximately half of individuals with TBI experience incomplete recovery or persistent symptoms six months post-injury. This study, utilizing a double-blind, placebo-controlled trial design, will enroll 40 participants with chronic TBI symptoms, randomly assigning them to receive either ibogaine or a placebo. Standardized assessments will evaluate the effectiveness of ibogaine in managing TBI symptoms and enhancing participants' quality of life.
The collaboration between Barrow Neurological Institute, Barrow Neuro Analytics Center, and Arizona State University researchers is a testament to the power of interdisciplinary research. By combining expertise in neurology, analytics, and life sciences, the team aims to unlock new insights into ibogaine's therapeutic potential. Anna Burke, MD, a neuropsychiatrist and chair of dementia research at Barrow, leads the study as the principal investigator, while Barrow physician-scientists Michael T. Lawton, MD, Susan Herman, MD, and Chia-Ling Phuah, MD, MMSc, contribute their expertise as co-investigators.
Dr. Lawton emphasizes the study's broader implications, stating that it represents the next chapter in neuroscience research. By exploring ibogaine's effects on the brain and mind, the study aims to enhance our understanding of brain circuitry and functionality. This knowledge could pave the way for novel treatments for PTSD and TBI, as well as contribute to our understanding of the mind's perception of the world and the influence of pharmacology.
However, the study's success hinges on participant recruitment. Researchers aim to enroll the first participant in 2027, with the trial expected to last several years. The study's outcome will not only impact the lives of individuals with TBI but also shape the future of neurological research and treatment.
